Toxicokinetics Data Summary
Compound: Isoeugenol/ Analyte: Isoeugenol
CAS Number: 97-54-1

Request Date: 7/11/2023
Request Time: 10:03:16
Lab: Battelle Northwest Laboratory

Treatment Group (mg/kg)
35 IV Plasma ${ }^{\text {a,c }} \quad 35$ Gavage Plasma $^{\text {b }} \quad 70$ Gavage Plasma $^{\text {b }} \quad 140$ Gavage Plasma $^{\text {b }}$

| C_Omin_pred (ug/mL) | $17.1 \pm 3.0$ |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Cmax_obs (ug/mL) |  | $1.13 \pm 0.18$ | $1.27 \pm 0.13$ | $1.91 \pm 0.14$ |
| Tmax_obs (min) |  | 20 | 10 | 20 |
| Alpha ( $\mathrm{min}^{-1}$ ) | $0.0872 \pm 0.0068$ |  |  |  |
| Alpha Half-life (min) | $7.95 \pm 0.62$ |  |  |  |
| Beta ( $\mathrm{min}^{-1}$ ) | $0.00587 \pm 00162$ |  |  |  |
| Beta Half-life ( $\mathrm{min}^{-1}$ ) | $118 \pm 33$ |  |  |  |
| $\mathrm{Cl}\left(\mathrm{mLmin}^{-1} \mathrm{~kg}^{-1}\right)$ | $148 \pm 5$ |  |  |  |
| Cl1_F (mL* $\mathrm{min}^{*} \mathrm{mLmin}-1^{*} \mathrm{~kg}^{-1}$ ) |  | $522 \pm 24$ | $595 \pm 26$ | $690 \pm 50$ |
| V1 (L/kg) | $25.2 \pm 7.0$ |  |  |  |
| AUC_0-T ( $\mathrm{ug} \mathrm{mL}^{-1} \mathrm{~min}$ ) | $197 \pm 6$ | $67.0 \pm 3.1$ | $118 \pm 5$ | $203 \pm 15$ |
| AUCinf_pred (ug mL ${ }^{-1} \mathrm{~min}$ ) | $208 \pm 23$ |  |  |  |
| F (percent) |  | $34 \pm 4$ |  |  |

Request Date: 7/11/2023
Request Time: 10:03:16
Lab: Battelle Northwest Laboratory

Female
Treatment Group (mg/kg)
35 IV Plasma ${ }^{\text {a,c }} 35$ Gavage Plasma $^{\text {b }} \quad 70$ Gavage Plasma $^{\text {b }} \quad 140$ Gavage Plasma $^{\text {b }}$

| C_Omin_pred (ug/mL) | $18.0 \pm 2.5$ |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Cmax_obs (ug/mL) |  | $1.94 \pm 0.17$ | $2.54 \pm 0.17$ | $3.99 \pm 2.10$ |
| Tmax_obs (min) |  | 10 | 20 | 5 |
| Alpha ( $\mathrm{min}^{-1}$ ) | $0.0666 \pm 0.0045$ |  |  |  |
| Alpha Half-life (min) | $10.4 \pm 0.7$ |  |  |  |
| Beta ( $\mathrm{min}^{-1}$ ) | $0.00679 \pm 0.00131$ |  |  |  |
| Beta Half-life ( $\mathrm{min}^{-1}$ ) | $102 \pm 20$ |  |  |  |
| $\mathrm{Cl}\left(\mathrm{mLmin}^{-1} \mathrm{~kg}^{-1}\right)$ |  | $108 \pm 2$ |  |  |
| Cl1_F (mL* $\mathrm{min}^{*} \mathrm{mLmin}-1^{*} \mathrm{~kg}^{-1}$ ) |  | $348 \pm 14$ | $338 \pm 18$ | $350 \pm 31$ |
| V1 (L/kg) | $16.0 \pm 3.1$ |  |  |  |
| AUC_0-T (ug mL-1 min) | $278 \pm 3$ | $101 \pm 4$ | $207 \pm 11$ | $400 \pm 36$ |
| AUCinf_pred (ug mL- ${ }^{-1} \mathrm{~min}$ ) | $284 \pm 25$ |  |  |  |
| $F$ (percent) |  | $36 \pm 3$ |  |  |

Toxicokinetics Data Summary
Compound: Isoeugenol/ Analyte: Isoeugenol

Request Date: 7/11/2023
Request Time: 10:03:16
Lab: Battelle Northwest Laboratory

## LEGEND

## MODELING SOFTWARE

PROC NLIN

## MODELING METHOD \& BEST FIT MODEL

${ }^{a}$ A nonlinear least-squares fitting program SAS PROC NLIN, SAS Institute, Inc., Cary, NC. Elimination of IEG was modeled for both species using a biphasic exponential equation $C(t)=$ Aoe $^{-a l p h a}{ }^{*} t+$ Boe $^{- \text {beta }^{* t}}()$ where $C(t)$ is the plasma IEG concentration at any post-administration time ( t$)$, alpha and beta are the rate constants (min-1) obtained from the fit, Ao and Bo are the intercepts on the ordinate (concentration) axis of the extrapolated initial and terminal phases, respectively. weighting factor of [mean plasma IEG concentration]-2.
${ }^{\text {b }}$ Manual, Plasma MEG concentration-versus-time profiles for both species were characterized by an early absorption phase followed by at least one secondary peak which prevented estimation of elimination rates. No modeling was done on the oral gavage data. Parameters were calculated using observed values.

## EXCEPTIONS

${ }^{\mathrm{c}} \mathrm{C}$ is total clearance, V 2 represent Vapp

## ANALYTE

Isoeugenol

## TK PARAMETERS

C_Omin_pred = Fitted plasma concentration at time zero (IV only)
Cmax_obs = Observed or Predicted Maximum plasma (or tissue) concentration
Tmax_obs = Time at which Cmax predicted or observed occurs
Alpha = Hybrid rate constant of the alpha phase
Alpha Half-life = Half-life of the alpha phase
Beta $=$ Hybrid rate constant of the beta phase
Beta Half-life = Half-life of the beta phase

Route: Intravenous, Gavage
Species/Strain: Mouse/B6C3F1

Toxicokinetics Data Summary
Request Date: 7/11/2023

CAS Number: 97-54-1
Request Time: 10:03:16
Lab: Battelle Northwest Laboratory

## TK PARAMETERS (cont'd)

$\mathrm{Cl}=$ Clearance, includes total clearance
Cl1_F = Apparent clearance of the central compartment, also Cl_F for gavage groups in non-compartmental model
V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA,
Vapp apparent volume of distribution for intravenous studies
AUC_0-T = Area under the plasma concentration versus time curve, AUC, from time ti (initial) to tf (final), AUClast
AUCinf_pred = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity
$\mathrm{F}=$ Bioavailability, absolute bioavailability

## TK PARAMETERS PROTOCOL

## ANALYSIS METHOD

Plasma Isoeugenol (IEG) concentrations were measured using a validated gas chromatography-mass spectrometry (GC-MS) method. Plasma level of detection (LOD) is $0.0009 \mathrm{ug} / \mathrm{mL}$, the limit of quantitation (LOQ) is $0.0031 \mathrm{ug} / \mathrm{mL}$ and the plasma experimental level of detection ELOQ is 0.015 $\mathrm{ug} / \mathrm{mL}$. All IV dosed mice IEG concentrations were above the LOD and only 14 out of 83 measurements fell between the LOD and the ELOQ.

TK_INTRAVENOUS PLASMA
$35 \mathrm{mg} / \mathrm{kg}$ Male and Female

Animals were weighed the morning of dosing for calculation of the dosing volume. Non-fasted mice were given a single bolus intravenous injection through a Silastic catheter surgically implanted by the supplier followed by approximately 0.2 mL of heparinized saline solution (10 units $/ \mathrm{mL}$ ). Three mice/sex were bled at each time point with the exception of the last time point for males where only two animals were available for bleeding. Each mouse was bled only once and the maximum amount of blood was collected via a closed chest cardiac puncture. 14 time points. Animals were anesthetized with approximately 70 percent $\mathrm{CO} 2-30$ percent 02 .

Toxicokinetics Data Summary

## Compound: Isoeugenol/ Analyte: Isoeugenol

CAS Number: 97-54-1

Request Date: 7/11/2023
Request Time: 10:03:16
Lab: Battelle Northwest Laboratory

TK PARAMETERS PROTOCOL (cont'd)

TK_GAVAGE PLASMA
$35 \mathrm{mg} / \mathrm{kg}, 70 \mathrm{mg} / \mathrm{kg}, 140 \mathrm{mg} / \mathrm{kg}$ Male and Female

Animals were weighed the day prior to dosing for calculation of the dosing volume and given a single gavage dose the next morning. Three mice/sex were bled at each time point with the exception of the last time point for males where only two animals were available for bleeding. Each mouse was bled only once and the maximum amount of blood was collected via a closed chest cardiac puncture. 14 time points. Animals were anesthetized with approximately 70 percent CO2-30 percent 02 .

